SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative ...
Centogene NV and Twist Bioscience Corp. are linking up to develop custom assay kits for rare disease testing. The companies said the collaboration aims to make genetic tests more accessible to rare ...
Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosis Combines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline ...
Centogene (NASDAQ:CNTG) said it extended its collaboration with Takeda Pharmaceutical (NYSE:TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed one-year agreement, ...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, ...
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE ...
The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis plays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results